Jeong Hwa Lee

Jeong Hwa Lee

Auto-generated profile, based on publicly available information

Jeong Hwa Lee

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2025 in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Verified
Journal Article
Open access
PDF file
JLJeong Hwa Lee
Jeong Hwa Lee
YKYong Hwan Kwon
Yong Hwan Kwon
SKSang Un Kim
Sang Un Kim
JPJi Hye Park
Ji Hye Park
JCJoon Hyun Cho
Joon Hyun Cho
SJSeong Woo Jeon
Seong Woo Jeon
Objectives: Recent trends have shown reduced success rates of the standard triple therapy, underscoring the need for updated data on the antimicrobial resistance of Helicobacter pylori. This study aimed to assess the antibiotic resistance rates of H. pylori strains in the Daegu–Kyungpook region and compare them with other regions in South Korea to provide evidence for eradication therapy guidelines. Methods: Between September 2022 and February 2024, samples from 100 patients aged 20–80 years with suspected H. pylori infections were collected across five medical institutions in the Daegu–Kyungpook region. The cultured strains were subjected to antimicrobial susceptibility testing. The minimum inhibitory concentrations for antibiotics were established using agar dilution methods, with breakpoints set at >0.125 μg/mL for amoxicillin, >0.25 μg/mL for clarithromycin, >1 μg/mL for tetracycline, >1 μg/mL for levofloxacin, and >8 μg/mL for metronidazole. Results: Among the 100 samples collected, cultures were performed for 98 samples, excluding 2 that tested negative in the rapid urease test or polymerase chain reaction. Of these, 73 (74%) samples were successfully cultured, while 25 (26%) failed. Among the 73 successful cultures, resistance was observed in 20 (27%) samples for amoxicillin, 25 (34%) for clarithromycin, 34 (47%) for metronidazole, 19 (26%) for tetracycline, and 27 (37%) for levofloxacin. Conclusions: This study showed an overall increasing trend in antibiotic resistance rates, particularly in clarithromycin resistance, emphasizing the need to reconsider first-line triple therapy. This study is the first multicenter investigation of H. pylori antibiotic resistance in the Daegu–Kyungpook region, contributing valuable insights for developing region-specific treatment guidelines.

22 June 2026 in Gut and Liver
Verified
Journal Article
Open access
JLJeong Hwa Lee
Jeong Hwa Lee
HCHae Chang Cho
Hae Chang Cho
JCJae Myung Cha
Jae Myung Cha
BYByong Duk Ye
Byong Duk Ye
SHSung Wook Hwang
Sung Wook Hwang
EKEun Soo Kim
Eun Soo Kim
Upadacitinib, a selective Janus kinase 1 inhibitor, has demonstrated efficacy in moderate-to-severe inflammatory bowel disease (IBD). Although its safety profile has been well established, genitourinary adverse events have rarely been reported. We present the first case series of semen discoloration associated with upadacitinib use in patients with ulcerative colitis and Crohn's disease. We retrospectively reviewed the medical records of six male IBD patients who developed semen discoloration during upadacitinib therapy at four referral hospitals in South Korea. Data on symptom onset, severity, and persistence were collected and analyzed. All six patients exhibited bluish or greenish semen after a median of 2 months of daily therapy with 45 mg upadacitinib. None of the patients exhibited urologic symptoms or infectious causes. Three patients reported reduced intensity and frequency of discoloration after the dose was reduced to 30 mg, while two achieved complete resolution following dose reduction to 15 mg or drug discontinuation. Urologic evaluations, including semen analysis, revealed no abnormalities. This is the first report documenting semen discoloration as a potential adverse event of upadacitinib therapy in IBD. Semen discoloration appears to be a rare, dose-related, and reversible adverse event associated with high-dose upadacitinib therapy. Further studies are needed to clarify the underlying mechanisms and long-term clinical implications.